NCT05022862Recruiting
Economic Incentives and vDOT for Latent Tuberculosis Infection
Economic Incentives and Video Directly Observed Therapy to Promote Adherence to Latent Tuberculosis Infection
Source: ClinicalTrials.gov · Last updated 4 May 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate a novel and scalable intervention that combines Video Directly Observed Therapy (vDOT) and financial incentives to promote completion of treatment for latent tuberculosis. Adult participants who are initiating treatment for latent tuberculosis will be recruited from the Baltimore City Health Department. The primary hypothesis is that the incentive intervention will increase the percentage of participants that complete the treatment for latent tuberculosis above the completion rates of participants receiving usual care.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 399 (estimated)
- First submitted
- 20 Aug 2021
- Start date
- 7 Feb 2022
- Primary completion date
- 1 Jun 2027
- Lead sponsor
- Johns Hopkins University
- Diseases
- Tuberculosis
- NCT number
- NCT05022862
What you commit to
- Study type: Interventional
- Planned participants: 399
- From 7 Feb 2022 to the primary completion date, 1 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- younger than 18 years old
- pregnant women (as determined by non-study directed clinical evaluation; BCHD performs urine pregnancy testing on women of child bearing age when indicated)
Other
- diagnosed with active TB
- prescribed an alternative treatment regimen for latent TB
- participant's spoken language does not have a translated long or short consent form
Who the study is looking for
- 18 years old or older,
- diagnosed with latent TB and determined to be appropriate for latent TB treatment by participants clinicians
- reside in Baltimore metro area
- speaks English or Spanish, or a language for which there is a short form available via the Johns Hopkins Medicine Institutional Review Board
- prescribed 3 months Isoniazid/Rifapentine, prescribed 3 months Isoniazid/Rifampin, or 4 months Rifampin
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Baltimore City Health Department, and Baltimore metropolitan area clinics and health departments Coordinator of this site? Confirm its status | Baltimore | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.